Cover Image
Market Research Report

North America Drug Discovery Market Forecast 2019-2027

Published by Inkwood Research Product code 609209
Published Content info 98 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Drug Discovery Market Forecast 2019-2027
Published: August 12, 2019 Content info: 98 Pages
Description

KEY FINDINGS

The revenue generated by the North American drug discovery market is expected to escalate from $XX million to $XX million during the projected period of 2019-2027. The North America region is estimated to capture XX% market share in the global drug discovery market by 2027 while evolving at a CAGR of 8.63% during the forecast period. The technological advancements and elevating healthcare expenditure accompanied by other aspects, is fueling the growth of the drug discovery market in the region.

MARKET INSIGHTS

The drug discovery market of North America is influenced by the trends in economies of the United States and Canada. The Canada drug discovery market is driven by surging demand for the small molecule drugs and rising incidences of chronic diseases like cancer. In Canada, around 30% of total deaths is caused due to cancer, which surges the demand for small molecule drugs in the country, thereby boosting the drug discovery market growth. Also, Canada has good infrastructure and expertise in manufacturing complex for drug discovery, which further fuels the market growth.

COMPETITIVE INSIGHTS

Some of the established players in the drug discovery market include Antares Pharma, 3M Company, Bayer AG, Eli Lily, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, and Becton, Dickinson & Company (BD). The dominant companies focus on corporate strategies to maintain a strong position in the market.

Table of Contents
Product Code: 13806

Table of contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. HIGH PREVALENCE RATES OF MAJOR HEALTH DISORDERS
    • 3.2.2. IMPLEMENTATION OF DRUG DISCOVERY PROGRAMS
    • 3.2.3. BIOINFORMATICS IS THE WIDELY USED DRUG DISCOVERY TECHNOLOGY
    • 3.2.4. SMALL MOLECULE DRUG TYPE CONSTITUTES THE HIGHEST MARKET SHARE
    • 3.2.5. CONTRACT RESEARCH ORGANIZATIONS (CROS) ARE THE FASTEST-GROWING END USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. AGING POPULATION
    • 4.2.2. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.2.3. GROWING HEALTHCARE EXPENDITURE
    • 4.2.4. TECHNOLOGICAL ADVANCEMENT
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. DELAY IN PRODUCT LAUNCHES
    • 4.3.2. POOR ACCESS TO HEALTHCARE SERVICES IN DEVELOPING MARKETS
    • 4.3.3. SHIFT FROM BRANDED TO GENERIC DRUGS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. EXTENSIVE R & D FOR NEW PRODUCT LAUNCHES
    • 4.4.2. INCREASING DEMAND FOR SPECIALTY MEDICINES
    • 4.4.3. RISING INVESTMENT BY PHARMACEUTICAL COMPANIES IN IMPROVING BIG-DATA ANALYTICAL CAPABILITIES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. COST BARRIER FOR LOCAL PEOPLE IN EMERGING ECONOMIES
    • 4.5.2. STRINGENT GOVERNMENT REGULATIONS

5. MARKET BY TECHNOLOGY

  • 5.1. HIGH THROUGHPUT SCREENING
  • 5.2. BIOCHIPS
  • 5.3. BIOINFORMATICS
  • 5.4. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 5.5. COMBINATORIAL CHEMISTRY
  • 5.6. NANOTECHNOLOGY
  • 5.7. SPECTROSCOPY
  • 5.8. METABOLOMICS
  • 5.9. OTHER TECHNOLOGIES

6. MARKET BY DRUG TYPE

  • 6.1. SMALL MOLECULE DRUG
  • 6.2. BIOLOGIC DRUG

7. MARKET BY SERVICE

  • 7.1. DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
  • 7.2. CHEMICAL SERVICES
  • 7.3. BIOLOGICAL SERVICES
  • 7.4. OTHER PHARMACEUTICAL SERVICES

8. MARKET BY END USER

  • 8.1. RESEARCH INSTITUTES
  • 8.2. PHARMACEUTICAL COMPANIES
  • 8.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 8.4. OTHER END USER

9. KEY ANALYTICS

  • 9.1. PORTER'S FIVE FORCES MODEL
    • 9.1.1. THREATS OF NEW ENTRANTS
    • 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 9.1.3. BARGAINING POWER OF BUYERS
    • 9.1.4. BARGAINING POWER OF SUPPLIERS
  • 9.2. COMPETITIVE RIVALRY
  • 9.3. VALUE CHAIN ANALYSIS
  • 9.4. PESTLE ANALYSIS
  • 9.5. REGULATORY FRAMEWORK
  • 9.6. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS

  • 10.1. NORTH AMERICA
    • 10.1.1. THE UNITED STATES
    • 10.1.2. CANADA

11. COMPANY PROFILES

  • 11.1. 3M COMPANY
  • 11.2. ANTARES PHARMA
  • 11.3. ASTRAZENECA PLC
  • 11.4. BAYER AG
  • 11.5. BECTON, DICKINSON & COMPANY (BD)
  • 11.6. BOEHRINGER INGELHEIM
  • 11.7. ELI LILY
  • 11.8. F. HOFFMANN-LA ROCHE LTD
  • 11.9. GLAXOSMITHKLINE LLC
  • 11.10. JOHNSON AND JOHNSON
  • 11.11. MERCK & CO. INC.
  • 11.12. NOVARTIS
  • 11.13. PFIZER, INC.
  • 11.14. SANOFI

LIST OF TABLES

  • TABLE 1 NORTH AMERICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • TABLE 2 NORTH AMERICA DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2019-2027 ($ MILLION)
  • TABLE 3 NORTH AMERICA HIGH THROUGHPUT SCREENING MARKET, 2019-2027 ($ MILLION)
  • TABLE 4 NORTH AMERICA BIOCHIPS MARKET, 2019-2027 ($ MILLION)
  • TABLE 5 NORTH AMERICA BIOINFORMATICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 6 NORTH AMERICA PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 7 NORTH AMERICA COMBINATORIAL CHEMISTRY MARKET, 2019-2027 ($ MILLION)
  • TABLE 8 NORTH AMERICA NANOTECHNOLOGY MARKET, 2019-2027 ($ MILLION)
  • TABLE 9 NORTH AMERICA SPECTROSCOPY MARKET, 2019-2027 ($ MILLION)
  • TABLE 10 NORTH AMERICA METABOLOMICS MARKET, 2019-2027 ($ MILLION)
  • TABLE 11 NORTH AMERICA OTHER TECHNOLOGIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 12 NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG TYPE, 2019-2027 ($ MILLION)
  • TABLE 13 NORTH AMERICA SMALL MOLECULE DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 14 NORTH AMERICA BIOLOGIC DRUG MARKET, 2019-2027 ($ MILLION)
  • TABLE 15 NORTH AMERICA DRUG DISCOVERY MARKET, BY SERVICE, 2019-2027 ($ MILLION)
  • TABLE 16 NORTH AMERICA DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 17 NORTH AMERICA CHEMICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 18 NORTH AMERICA BIOLOGICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 19 NORTH AMERICA OTHER PHARMACEUTICAL SERVICES MARKET, 2019-2027 ($ MILLION)
  • TABLE 20 NORTH AMERICA DRUG DISCOVERY MARKET, BY END USER, 2019-2027 ($ MILLION)
  • TABLE 21 NORTH AMERICA RESEARCH INSTITUTES MARKET, 2019-2027 ($ MILLION)
  • TABLE 22 NORTH AMERICA PHARMACEUTICAL COMPANIES MARKET, 2019-2027 ($ MILLION)
  • TABLE 23 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS (CROS) MARKET, 2019-2027 ($ MILLION)
  • TABLE 24 NORTH AMERICA OTHER END USER MARKET, 2019-2027 ($ MILLION)
  • TABLE 25 NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, 2019-2027 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 2 NORTH AMERICA DRUG DISCOVERY MARKET SHARE BY TECHNOLOGY 2018 & 2027 (%)
  • FIGURE 3 NORTH AMERICA DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2019-2027 ($ MILLION)
  • FIGURE 4 NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOCHIPS, 2019-2027 ($ MILLION)
  • FIGURE 5 NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2019-2027 ($ MILLION)
  • FIGURE 6 NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2019-2027 ($ MILLION)
  • FIGURE 7 NORTH AMERICA DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY 2019-2027 ($ MILLION)
  • FIGURE 8 NORTH AMERICA DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2019-2027 ($ MILLION)
  • FIGURE 9 NORTH AMERICA DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2019-2027 ($ MILLION)
  • FIGURE 10 NORTH AMERICA DRUG DISCOVERY MARKET, BY METABOLOMICS, 2019-2027 ($ MILLION)
  • FIGURE 11 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2019-2027 ($ MILLION)
  • FIGURE 12 NORTH AMERICA DRUG DISCOVERY MARKET SHARE BY DRUG TYPE 2018 & 2027 (%)
  • FIGURE 13 NORTH AMERICA DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2019-2027 ($ MILLION)
  • FIGURE 14 NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2019-2027 ($ MILLION)
  • FIGURE 15 NORTH AMERICA DRUG DISCOVERY MARKET SHARE BY SERVICE 2018 & 2027 (%)
  • FIGURE 16 NORTH AMERICA DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 17 NORTH AMERICA DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES 2019-2027 ($ MILLION)
  • FIGURE 18 NORTH AMERICA DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 19 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2019-2027 ($ MILLION)
  • FIGURE 20 NORTH AMERICA DRUG DISCOVERY MARKET SHARE BY END USER 2018 & 2027 (%)
  • FIGURE 21 NORTH AMERICA DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2019-2027 ($ MILLION)
  • FIGURE 22 NORTH AMERICA DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2019-2027 ($ MILLION)
  • FIGURE 23 NORTH AMERICA DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), 2019-2027 ($ MILLION)
  • FIGURE 24 NORTH AMERICA DRUG DISCOVERY MARKET, BY OTHER END USER, 2019-2027 ($ MILLION)
  • FIGURE 25 PORTER'S FIVE FORCE MODEL
  • FIGURE 26 NORTH AMERICA DRUG DISCOVERY MARKET, REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 27 THE UNITED STATES DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
  • FIGURE 28 CANADA DRUG DISCOVERY MARKET, 2019-2027 ($ MILLION)
Back to Top